CX 5461 clinical trials
Also written CX-5461 and Pidnarulex.
How each study uses CX 5461 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CX 5461 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2016 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 5
National Cancer Institute (NCI) (3) · Senhwa Biosciences, Inc. (1) · Canadian Cancer Trials Group (1) · Peter MacCallum Cancer Centre, Australia (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test CX 5461.
- Dec 2026Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid CancersPhase 1 · National Cancer Institute (NCI)
- Mar 2027Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationPhase 1 · Senhwa Biosciences, Inc.
Studies
Open first, then newest update. How each study uses CX 5461 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT07137416Written as PidnarulexHow we know
- Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneRecruitingPhase 1/2National Cancer Institute (NCI)NCT07069699Written as PidnarulexHow we know
- Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid CancersRecruitingPhase 1National Cancer Institute (NCI)NCT06606990Written as PidnarulexHow we know
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationActive, not recruitingPhase 1Senhwa Biosciences, Inc.NCT04890613Written as CX-5461How we know
- Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerTerminatedPhase 1Peter MacCallum Cancer Centre, AustraliaNCT05425862Written as PidnarulexHow we know
- A Phase I Study of CX5461CompletedPhase 1Canadian Cancer Trials GroupNCT02719977Written as CX5461How we know
Given beside what is tested · 1 — CX 5461 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 21, 2026.
Stopped1
- Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerTerminatedNov 2, 2026NCT05425862
Codes
What other systems call CX 5461 · ClinicalTrials.gg INT005818
- MeSH (NLM) C557717CX 5461One source ClinicalTrials.gov
- UNII (FDA) 3R4C5YLB9IPIDNARULEXConfirmed FDA, Wikidata
- Wikidata Q27166854cx-5461Confirmed FDA, Wikidata
- DrugBank DB16846One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C557717 | CX 5461 | One source ClinicalTrials.gov |
| UNII (FDA) | 3R4C5YLB9I | PIDNARULEX | Confirmed FDA, Wikidata |
| Wikidata | Q27166854 | cx-5461 | Confirmed FDA, Wikidata |
| DrugBank | DB16846 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.